undamentalytics Newsletter
Sign in

Vivosim Labs, Inc. revenue

Vivosim Labs, Inc.'s revenue was $131,000 in fiscal 2026, down 9.0% on the year before. Since fiscal 2011 ($603,000) it has grown at a compound -9.7% a year. Over the last twelve months it was $112,000.

Revenue history

US$ thousands unless shown otherwise. Fiscal years, plus the last twelve months (LTM) when newer.

Fiscal year2011Dec 20102012Dec 20112013Dec 20122014Mar 20142015Mar 20152016Mar 20162017Mar 20172018Mar 20182019Mar 20192020Mar 20202021Mar 20212022Mar 20222023Mar 20232024Mar 20242025Mar 20252026Mar 2026LTMJun 2026
Revenue6039691,1973795711,4834,2304,6033,0912,19601,500370109144131112
Growth on the year before—+60.7%+23.5%−68.3%+50.7%+159.7%+185.2%+8.8%−32.8%−29.0%−100.0%—−75.3%−70.5%+32.1%−9.0%—
Gross profit————5711,4833,2743,6032,5911,8960———139131—
Gross margin————100.0%100.0%77.4%78.3%83.8%86.3%————96.5%100.0%—

Revenue as reported in the company's 10-K and 10-Q filings (for banks, net interest income plus non-interest income). Growth is left blank when the earlier figure was zero or negative.

Where the revenue comes from

Fiscal year to March 31, 2026
Products and services
Line of business Revenue Share YoY
Royalty $131,000 100.0% ▲ 10.1%
Products $0 0.0% ▼ 100.0%

From Vivosim Labs, Inc.'s 10-K filed July 14, 2026, as tagged in the filing. View filing. Indented rows are part of the line above; their share is of that line. In the bars, the faint bar behind is the year before.

Revenue against peers

Biotechnology: the closest covered companies by revenue. Last twelve months.

CompanyRevenueGrowth3-year growth a year
Vivosim Labs, Inc. $112,000 -21.1% -36.9%
Ibio, Inc. $100,000 -75.0% -62.4%
Lisata Therapeutics, Inc. $100,000 -90.7% —
AIM Immunotech Inc. $95,000 -21.5% -17.3%
Celldex Therapeutics, Inc. $158,000 -97.3% -63.5%
Clene Inc. $197,000 -31.1% -36.9%

Compare with peers

Head to head: IBIO vs VIVSLSTA vs VIVSAIM vs VIVS

More: Biotechnology stocks compared, Health Care sector, rankings of US companies

Figures from Vivosim Labs, Inc.'s SEC filings (10-K and 10-Q), retrieved October 29, 2026. How we read and check them: methodology and data sources. Not investment advice. Back to Vivosim Labs, Inc.